| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adverse Drug Reactions from Database to Prescriber: The United Kingdom Experience
|
Fallowfield, Joseph M.
|
|
1995
|
29 |
1 |
p. 327-333
|
artikel
|
| 2 |
A Guide to Effective Presentation Skills for Drug Information Personnel
|
Pakes, Gary E.
|
|
1995
|
29 |
1 |
p. 139-146
|
artikel
|
| 3 |
A Model for an End User Computer Validation Control System in a Research Laboratory Environment
|
Ryerson, Bruce A.
|
|
1995
|
29 |
1 |
p. 155-162
|
artikel
|
| 4 |
An Autoencoder for Clinical and Regulatory Data Processing
|
Gillum, Terry L.
|
|
1995
|
29 |
1 |
p. 107-113
|
artikel
|
| 5 |
A Short Practical Method for Triage of Adverse Drug Reactions
|
Jain, K. K.
|
|
1995
|
29 |
1 |
p. 339-342
|
artikel
|
| 6 |
Challenges in International Harmonization
|
Nightingale, Stuart L.
|
|
1995
|
29 |
1 |
p. 1-9
|
artikel
|
| 7 |
Clinical Data Acquisition using Five-Part NCR Case Record forms and Overnight Delivery
|
Barranco, Charles P.
|
|
1995
|
29 |
1 |
p. 61-67
|
artikel
|
| 8 |
Clinical Trial Initiation Procedures in Europe: The Legal Framework and Practical Aspects*
|
Legrand, C.
|
|
1995
|
29 |
1 |
p. 201-259
|
artikel
|
| 9 |
Computerized Bayesian Evaluation of Adverse Events
|
Lanctôt, Krista L.
|
|
1995
|
29 |
1 |
p. 319-325
|
artikel
|
| 10 |
Confidentiality of Databases: The View of One Pharmaceutical Company
|
Pierredon, Marc A.
|
|
1995
|
29 |
1 |
p. 351-353
|
artikel
|
| 11 |
Confidentiality of Medical Databases and Pharmaco-Epidemiology
|
Ham, M. ten
|
|
1995
|
29 |
1 |
p. 343-349
|
artikel
|
| 12 |
Dechallenge Revisited
|
Stephens, Myles D.
|
|
1995
|
29 |
1 |
p. 335-338
|
artikel
|
| 13 |
Delta: The True Clinically Significant Difference to be Detected
|
Bristol, David R.
|
|
1995
|
29 |
1 |
p. 33-36
|
artikel
|
| 14 |
Drug Monitoring in Developing Countries: A Drug Regulator's Perspective
|
Folb, Peter I.
|
|
1995
|
29 |
1 |
p. 303-305
|
artikel
|
| 15 |
Drug Monitoring in Latin America
|
Chaves, Albin
|
|
1995
|
29 |
1 |
p. 87-89
|
artikel
|
| 16 |
Drug Safety: A Clinical Pharmacologist's Perspective
|
Honig, Peter K.
|
|
1995
|
29 |
1 |
p. 127-130
|
artikel
|
| 17 |
Drug Safety: Legal Requirements in Europe and in the United States — A European Industry View
|
Juillet, Yves
|
|
1995
|
29 |
1 |
p. 291-295
|
artikel
|
| 18 |
European Legislation and Research Projects regarding Patient Education for Medication
|
Vander Stichele, Robert H.
|
|
1995
|
29 |
1 |
p. 285-290
|
artikel
|
| 19 |
Experience with an International Approval Process for Clinical Documents
|
Kuhnert, Betty R.
|
|
1995
|
29 |
1 |
p. 267-272
|
artikel
|
| 20 |
FDA 2000-Building for the Future
|
Veverka, Mary Jo
|
|
1995
|
29 |
1 |
p. 19-25
|
artikel
|
| 21 |
Guest Editor's Note
|
Herman, Raymond L.
|
|
1995
|
29 |
1 |
p. 313-313
|
artikel
|
| 22 |
How to Validate a Computer System
|
Cardie, Mary Lou
|
|
1995
|
29 |
1 |
p. 187-199
|
artikel
|
| 23 |
Increasing Subject Comprehension of the Informed Consent Form
|
Barter, Pauline A.
|
|
1995
|
29 |
1 |
p. 91-98
|
artikel
|
| 24 |
Intellectual Property Negotiations: A Managerial Perspective of Basic Intellectual Property Issues for Small Pharmaceutical Companies in Research Contract Negotiations with Contract Research Organizations
|
Macchetto, Claudio
|
|
1995
|
29 |
1 |
p. 131-137
|
artikel
|
| 25 |
Medical Knowledge: The Essential of Causality Assessment
|
Bénichou, Christian
|
|
1995
|
29 |
1 |
p. 315-318
|
artikel
|
| 26 |
Monitoring of Adverse Events and Reporting
|
Czarnecki, Andrzej
|
|
1995
|
29 |
1 |
p. 307-311
|
artikel
|
| 27 |
Partnering in Pharmaceutical Education: A Model to Help Industry Shape Health Care Reform
|
Giovenella, Albert J.
|
|
1995
|
29 |
1 |
p. 115-126
|
artikel
|
| 28 |
Patient Package Inserts for Prescription Drugs in an International Pharmaceutical Company
|
Amery, Willem K.
|
|
1995
|
29 |
1 |
p. 51-60
|
artikel
|
| 29 |
Phase IV Clinical Trials: Purposes, Design, and a Limited Place for Good Clinical Practice
|
Decoster, Genevieve
|
|
1995
|
29 |
1 |
p. 79-86
|
artikel
|
| 30 |
Points for Consideration in the Collection and Analysis of Safety Data
|
Chuang-Stein, Christy
|
|
1995
|
29 |
1 |
p. 37-44
|
artikel
|
| 31 |
Pricing and Reimbursement Regulation in Europe: The Industry Perspective
|
Reuben, Bryan G.
|
|
1995
|
29 |
1 |
p. 273-283
|
artikel
|
| 32 |
Reinventing Advisory Committee Management at the Food and Drug Administration
|
Golden, Minna S.
|
|
1995
|
29 |
1 |
p. 11-18
|
artikel
|
| 33 |
Responding to Drug Information Requests Using Rapid
|
Gasperino, Joseph
|
|
1995
|
29 |
1 |
p. 99-106
|
artikel
|
| 34 |
Sample Size for Therapeutic Equivalence Based on Confidence Interval
|
Lin, Stan C.
|
|
1995
|
29 |
1 |
p. 45-50
|
artikel
|
| 35 |
Standardizing Data Screening Tools
|
White, Marjory S.
|
|
1995
|
29 |
1 |
p. 181-186
|
artikel
|
| 36 |
Supporting Your Claims: Recent Issues in Cardiovascular Drugs
|
Chen, Shaw T.
|
|
1995
|
29 |
1 |
p. 27-32
|
artikel
|
| 37 |
Technical and Schedule Impacts of Environmental Assessments on the Drug Development Process
|
Velagaleti, Ranga
|
|
1995
|
29 |
1 |
p. 171-179
|
artikel
|
| 38 |
The European Community — Regulatory Affairs Post-1995
|
Helmanis, Ansis M.
|
|
1995
|
29 |
1 |
p. 261-265
|
artikel
|
| 39 |
The In-House Database — Nicety or Necessity?
|
Gretz, Marianne
|
|
1995
|
29 |
1 |
p. 163-169
|
artikel
|
| 40 |
The Portable Desktop Revisited: Present Status and Future Directions
|
Hopp, David I.
|
|
1995
|
29 |
1 |
p. 69-78
|
artikel
|
| 41 |
The Representation of Women in Clinical Drug Trials
|
Ritrovato, Charles A.
|
|
1995
|
29 |
1 |
p. 147-154
|
artikel
|
| 42 |
Vaccine Data Reporting: Standard, Yet Flexible
|
McCool, Kathleen
|
|
1995
|
29 |
1 |
p. 297-301
|
artikel
|
Tijdschrift beschrijving